Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology
暂无分享,去创建一个
A. Santoro | D. Bolignano | C. Zoccali | A. Peri | E. Fiaccadori | E. Ghigo | M. Plebani | F. Settanni | R. Pasquali | A. Cabassi | A. Peracino
[1] D. A. Miligy. Laboratory errors and patient safety. , 2015, International journal of health care quality assurance.
[2] D. Annane,et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia , 2014, Intensive Care Medicine.
[3] J. Verbalis,et al. Moderate Hyponatremia Is Associated with Increased Risk of Mortality: Evidence from a Meta-Analysis , 2013, PloS one.
[4] Arthur Greenberg,et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. , 2013, The American journal of medicine.
[5] K. Yalta,et al. Copeptin and cardiovascular disease: a review of a novel neurohormone. , 2013, International journal of cardiology.
[6] L. Bankir,et al. Vasopressin: a novel target for the prevention and retardation of kidney disease? , 2013, Nature Reviews Nephrology.
[7] G. Wuerzner,et al. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure. , 2013, The Journal of clinical endocrinology and metabolism.
[8] J. Li,et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] G. Lippi,et al. Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department , 2013, Clinical chemistry and laboratory medicine.
[10] R. Fenton,et al. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. , 2013, Endocrine reviews.
[11] Eiji Higashihara,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.
[12] J. Haymann,et al. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. , 2012, Kidney international.
[13] T. Rabelink,et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] B. Allolio,et al. Clinical review: Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. , 2012, The Journal of clinical endocrinology and metabolism.
[15] R. Gansevoort,et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[16] I. Gustafsson,et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. , 2012, Journal of cardiac failure.
[17] G. Lippi,et al. Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin , 2012, Clinical chemistry and laboratory medicine.
[18] Alan S Maisel,et al. Short-term mortality risk in emergency department acute heart failure. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[19] P. Ponikowski,et al. Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study , 2011, Circulation. Heart failure.
[20] P. Esposito,et al. The Syndrome of Inappropriate Antidiuresis: Pathophysiology, Clinical Management and New Therapeutic Options , 2011, Nephron Clinical Practice.
[21] A. Pfeiffer,et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome--revisiting the direct and indirect water deprivation tests. , 2011, The Journal of clinical endocrinology and metabolism.
[22] N. Morgenthaler,et al. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. , 2011, The Journal of clinical endocrinology and metabolism.
[23] E. J. van der Jagt,et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[24] J. Grantham,et al. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[25] J. Klein,et al. Arginine–vasopressin directly promotes a thermogenic and pro-inflammatory adipokine expression profile in brown adipocytes , 2010, Regulatory Peptides.
[26] D. Bolignano,et al. Vasopressin beyond water: implications for renal diseases , 2010, Current opinion in nephrology and hypertension.
[27] N. Morgenthaler,et al. Copeptin: a biomarker of cardiovascular and renal function. , 2010, Congestive heart failure.
[28] L. Groop,et al. Plasma Copeptin and the Risk of Diabetes Mellitus , 2010, Circulation.
[29] D. Goldfarb,et al. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[30] N. Holt,et al. Vasopressin: a review of therapeutic applications. , 2010, Journal of cardiothoracic and vascular anesthesia.
[31] F. Goffinet,et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. , 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[32] M. Molloy,et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[33] J. Laycock. INTRODUCTION TO VASOPRESSIN , 2009 .
[34] Jens C. Pruessner,et al. The brain and the stress axis: The neural correlates of cortisol regulation in response to stress , 2009, NeuroImage.
[35] M. Dünser,et al. Copeptin and the transplanted kidney: friends or foes? , 2009, Transplantation.
[36] V. Torres,et al. A case for water in the treatment of polycystic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[37] M. Palkovits,et al. Catecholaminergic systems in stress: structural and molecular genetic approaches. , 2009, Physiological reviews.
[38] J. Struck,et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. , 2009, Clinical science.
[39] N. Morgenthaler,et al. Copeptin in the differential diagnosis of hyponatremia. , 2008, The Journal of clinical endocrinology and metabolism.
[40] M. Konstam,et al. Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia , 2008, Circulation.
[41] J. Struck,et al. Copeptin: clinical use of a new biomarker , 2008, Trends in Endocrinology & Metabolism.
[42] J. Struck,et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. , 2007, The Journal of clinical endocrinology and metabolism.
[43] G. Brabant,et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. , 2007, The Journal of clinical endocrinology and metabolism.
[44] F. Gungor,et al. Transient gestational diabetes insipidus diagnosed in successive pregnancies: review of pathophysiology, diagnosis, treatment, and management of delivery , 2007, Pituitary.
[45] F. Endo,et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. , 2007, Molecular endocrinology.
[46] J. Struck,et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure , 2006, European journal of clinical investigation.
[47] J. Struck,et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. , 2006, Clinical chemistry.
[48] E. Laws,et al. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. , 2005, Journal of neurosurgery.
[49] S. Gitelman,et al. Nephrogenic syndrome of inappropriate antidiuresis. , 2005, The New England journal of medicine.
[50] T. Manolio. Novel risk markers and clinical practice. , 2003, The New England journal of medicine.
[51] J. Granton,et al. Science Review: Vasopressin and the cardiovascular system part 1 – receptor physiology , 2003, Critical care.
[52] J. G. Verbalis,et al. Diabetes insipidus. , 1997, Current therapy in endocrinology and metabolism.
[53] L. Rubenstein,et al. Hyponatremia in a Nursing Home Population , 1995, Journal of the American Geriatrics Society.
[54] K. Alberti,et al. THE EFFECT OF VASOPRESSIN INFUSION ON GLUCOSE METABOLISM IN MAN , 1985, Clinical endocrinology.
[55] F. Vinicor,et al. Plasma Vasopressin in Uncontrolled Diabetes Mellitus , 1979, Diabetes.